Acquisition Announced

UCB acquisition of Neurona Therapeutics

US$650m consideration

Announced 17 Apr 2026

Advisers

Neurona Therapeutics

Target

Financial adviser

UCB

Acquirer

Financial adviser
BofA Securities (as Bank of America)
Legal adviser
Target
Neurona Therapeutics
Acquirer
UCB
Target based in
United States
Buyer based in
Belgium
Sector
Biotech
Tags
Biotech, Cell Therapy, Pharma

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.